{"entity":{"id":"jihui-hao","kind":"person","name":"Jihui Hao","aka":[],"tldr":"Physician-scientist who is President of Tianjin Medical University Cancer Institute and Hospital, one of China's largest specialist cancer hospitals and a National Clinical Research Center for Malignant Tumors.","summary":"Jihui Hao (MD, PhD) is President of Tianjin Medical University Cancer Institute and Hospital (TMUCIH), the specialist tertiary cancer hospital of Tianjin Medical University in Hexi District, Tianjin. The hospital's English leadership page lists him as President alongside Party Secretary Jianguo Liu and vice presidents Xiaohui Cao, Lan Zhang, Jing Hei, Jun Shen, Dingzhi Huang and Hui Li. TMUCIH traces its origins to an 1861 clinic, opened China's first tumour ward in 1952 under Jin Xianzhai, took its current name in 1997 and was designated a National Clinical Research Center for Malignant Tumors in 2013, operating 36 clinical departments across several Tianjin campuses.","asOf":"2026-09-10","links":[{"label":"Source: TMUCIH leadership page","url":"http://www.tmucih.com/index/about/leaderships.html"},{"label":"Source: Wikipedia article on TMUCIH","url":"https://en.wikipedia.org/wiki/Tianjin_Medical_University_Cancer_Institute_and_Hospital"}],"tags":["leadership","clinician-scientist","hospital-management"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tmucih"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["oncotarget","nature-communications"],"dependsOn":[],"notes":[],"role":"President, Tianjin Medical University Cancer Institute and Hospital","institutionId":"tmucih","specialisms":["Surgical oncology","Hospital management","Cancer research"],"profiles":[{"label":"TMUCIH leadership page (English)","url":"http://www.tmucih.com/index/about/leaderships.html"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hao+J%5BAuthor%5D+AND+Tianjin+Medical+University+Cancer"}],"papers":[{"title":"Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer","journal":"Biomaterials","year":2015,"doi":"10.1016/j.biomaterials.2014.12.028"},{"title":"Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma","journal":"Oncotarget","year":2014,"doi":"10.18632/oncotarget.2948"},{"title":"Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression","journal":"Nature Communications","year":2017,"doi":"10.1038/ncomms14035"}]},"route":"/people/jihui-hao/","neighbours":{"institution":[{"id":"tmucih","kind":"institution","name":"Tianjin Medical University Cancer Institute and Hospital","route":"/institutions/tmucih/"}],"journal":[{"id":"nature-communications","kind":"journal","name":"Nature Communications","route":"/journals/nature-communications/"},{"id":"oncotarget","kind":"journal","name":"Oncotarget","route":"/journals/oncotarget/"}]}}